Perioperative Treatment in MIBC: When to Refer and What to Expect

Half of patients with MIBC never make it to perioperative therapy. In this video, Joshua J. Meeks, MD, PhD, unpacks the referral barriers behind that gap.

A single FDA update just erased the platinum-eligibility line dividing patients with MIBC. Joshua J. Meeks, MD, PhD, explains what changed on July 10 and why a new subcutaneous option could ease access for rural patients

For the first time in 25 years, a nonplatinum regimen beats cisplatin-based chemotherapy head-to-head. Joshua J. Meeks, MD, PhD, breaks down the KEYNOTE-B15/EV-304 data driving that shift.

With the recent FDA approval of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) in MIBC, Joshua J. Meeks, MD, PhD, maps the treatment timeline patients should expect and the skin reactions that warrant an urgent referral.

The data are compelling, but only if patients reach a medical oncologist. Joshua J. Meeks, MD, PhD, tackles the unresolved questions in MIBC care and lays out the referral steps every community urologist can take today.